- Home
- AGAE vs GTBP Comparison
AGAE vs GTBP Comparison
Compare AGAE & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGAE | GTBP |
|---|---|---|
| Founded | 2017 | 1965 |
| Country | United States | United States |
| Employees | 73 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 12.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | AGAE | GTBP |
|---|---|---|
| Price | $0.27 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.2M | 662.0K |
| Earning Date | 11-19-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.39 |
| 52 Week High | $3.79 | $3.73 |
Technical Indicators
Market Signals| Indicator | AGAE | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 38.67 |
| Support Level | $0.25 | $0.40 |
| Resistance Level | $0.33 | $0.59 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 13.40 | 39.47 |
Price Performance
Historical ComparisonAbout AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.